Kingsview Wealth Management’s Biogen BIIB Stock Holding History

Kingsview Wealth Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$253K	Buy	1,171 +15	+1%	+$2.87K	﹤0.01%	1262
2026 Q1	$212K	Buy	+1,156	New	+$213K	﹤0.01%	1228
2023 Q3	–	Sell	-1,101	Closed	-$314K	–	935
2023 Q2	$314K	Buy	+1,101	New	+$328K	0.01%	727
2017 Q4	–	Sell	-762	Closed	-$239K	–	398
2017 Q3	$239K	Buy	+762	New	+$226K	0.11%	239

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kingsview Wealth Management's BIIB Position: Q2 2026 in Review

Kingsview Wealth Management increased its Biogen (BIIB) stake by 1.3% in Q2 2026, buying an estimated $2.87K and bringing the position to 1,171 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #1262.

Kingsview Wealth Management first reported a position in BIIB in Q3 2017 and has held it in 4 quarters since. The position peaked at $314K in Q2 2023. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Kingsview Wealth Management held 1,171 shares of Biogen worth $253K as of Q2 2026.
Kingsview Wealth Management bought 15 Biogen shares in Q2 2026, an estimated $2.87K.
Biogen made up ﹤0.01% of Kingsview Wealth Management's portfolio in Q2 2026, its #1262 holding.
Kingsview Wealth Management first reported a position in Biogen in Q3 2017 and has held it in 4 quarters since.
Kingsview Wealth Management's Biogen position peaked at $314K in Q2 2023.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.